^
Association details:
| Biomarker: | TP53 wild-type |
|---|---|
| Cancer: | Liposarcoma |
| Drug: | siremadlin (HDM201) (MDM2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Results from a First-in-Human Phase I Study of Siremadlin (HDM201) in Patients with Advanced Wild-Type TP53 Solid Tumors and Acute Leukemia
Published date:
12/03/2021
Excerpt:
These included approximately 10 patients with TP53 wild-type liposarcoma (LPS)...patients with LPS in the
expansion group achieved excellent disease control.
DOI:
10.1158/1078-0432.CCR-21-1295
